Dublin, Dec. 14, 2023 (GLOBE NEWSWIRE) -- The "Omalizumab (Xolair) Biosimilars & Biosuperiors Pipeline Review" report has been added to ResearchAndMarkets.com's offering. This product provides basic ...
Excellergy's trifunctional ECRIs remove IgE from mast cells and basophils, neutralize free IgE, and downregulate FceRI expression, offering improved allergy control. Pre-clinical data supports ECRIs' ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results